CPT1A and metabolic dysfunction-associated steatohepatitis: Treatment with APE at 100 mg/kg substantially increased Cpt1a and Ppara mRNA levels to 1.06 ± 0.04-fold and 1.10 ± 0.19-fold, respectively, (p < 0.05 vs. NASH) (Figure 10c,d).